Therapeutic agents and uses thereof
AssigneeJanssen Biotech, Inc.
InventorsSven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
Life of this patent
Estimating the term…
Abstract
The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
Claims18
A method for the treatment of castration-resistant prostate cancer (CRPC) in a patient, the method comprising administering a therapeutically effective amount of an agent comprising
- (a) an antibody or antigen-binding fragment thereof with specificity for human glandular kallikrein (hK2) and
- (b) a cytotoxic moiety comprising 225Ac,
- wherein the antibody or antigen-binding fragment thereof with specificity for hK2 comprises the six complementarity determining regions (CDRs) of antibody 11B6, wherein the heavy chain of the 11B6 antibody comprises SEQ ID NO:
- 4 and the light chain of the 11B6 antibody comprises SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.